NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis $1.70 -0.15 (-7.95%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About bioAffinity Technologies Stock (NASDAQ:BIAF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIAF alerts:Sign Up Key Stats Today's Range$1.69▼$1.8550-Day Range$1.86▼$9.4352-Week Range$1.69▼$80.70Volume44,377 shsAverage Volume1.24 million shsMarket Capitalization$3.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for lung disease, including lung cancer. Its work centers on applying flow cytometry and other technologies to analyze biological samples and support earlier disease detection. The company’s lead product, CyPath Lung, is a laboratory-developed test that analyzes sputum samples using proprietary technology. It is intended to help assess lung cancer risk in patients with suspicious pulmonary nodules and is offered through the company’s clinical laboratory subsidiary, Precision Pathology Services. Based in San Antonio, Texas, bioAffinity Technologies also provides pathology and diagnostic laboratory services through Precision Pathology Services, including testing in areas such as cytopathology and molecular diagnostics. Its operations primarily serve the U.S. market.AI Generated. May Contain Errors. Read More bioAffinity Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreBIAF MarketRank™: 0.49438509997 of 5 starsbioAffinity Technologies scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingbioAffinity Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragebioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.Read more about bioAffinity Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of bioAffinity Technologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bioAffinity Technologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiobioAffinity Technologies has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.11% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bioAffinity Technologies has recently decreased by 19.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldbioAffinity Technologies does not currently pay a dividend.Dividend GrowthbioAffinity Technologies does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.17 News SentimentbioAffinity Technologies has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for bioAffinity Technologies this week, compared to 3 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders2.40% of the stock of bioAffinity Technologies is held by insiders.Percentage Held by Institutions1.64% of the stock of bioAffinity Technologies is held by institutions.Read more about bioAffinity Technologies' insider trading history. Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIAF Stock News HeadlinesbioAffinity Technologies Reports Record CyPath Lung Testing GrowthNovember 19 at 10:10 AM | tipranks.combioAffinity Reports Record October CyPath Lung Test VolumeNovember 17 at 8:31 AM | tipranks.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 20 at 1:00 AM | Porter & Company (Ad)bioAffinity Technologies (BIAF) Set to Post Quarterly Earnings on WednesdayNovember 17 at 1:44 AM | americanbankingnews.combioAffinity Technologies (NASDAQ:BIAF) Stock Rating Cut to Sell at Wall Street ZenNovember 14, 2026 | americanbankingnews.comBioAffinity Technologies reports record CyPath Lung test performed in OctoberNovember 11, 2026 | finance.yahoo.combioAffinity Technologies posts record monthly volume for CyPath Lung testNovember 11, 2026 | finance.yahoo.combioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitionsNovember 11, 2026 | finance.yahoo.comSee More Headlines BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed this year? bioAffinity Technologies' stock was trading at $17.70 at the beginning of 2026. Since then, BIAF shares have decreased by 90.3% and is now trading at $1.7250. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) issued its quarterly earnings data on Friday, November, 6th. The company reported ($5.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($31.50) by $25.61. The company earned $1.07 million during the quarter, compared to analyst estimates of $1.91 million. bioAffinity Technologies had a negative net margin of 278.90% and a negative trailing twelve-month return on equity of 293.44%. When did bioAffinity Technologies' stock split? bioAffinity Technologies shares reverse split on the morning of Friday, September 19th 2025.The 1-30 reverse split was announced on Wednesday, September 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an initial public offering (IPO) on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of bioAffinity Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Bollinger Innovations (BINI), Biostem Technologies (BSEM), Intel (INTC), Micron Technology (MU), NVIDIA (NVDA), Oncolytics Biotech (ONCY) and KeyCorp (KEY). Company Calendar Last Earnings11/06/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BIAF's financial health is in the Red zone, according to TradeSmith. BIAF has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:BIAF CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees57Year Founded2014Profitability EPS (Trailing Twelve Months)($44.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.91 million Net Margins-278.90% Pretax Margin-278.83% Return on Equity-293.44% Return on Assets-160.36% Debt Debt-to-Equity Ratio0.13 Current Ratio1.51 Quick Ratio1.47 Sales & Book Value Annual Sales$6.16 million Price / Sales0.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book0.80Miscellaneous Outstanding Shares1,820,000Free Float1,776,000Market Cap$3.15 million OptionableNot Optionable Beta-1.04 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:BIAF) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersI tested Elon's new tech myself and brought a camera crewElon Musk's new technology is already in 229 locations across 27 states plus D.C. In 2016, Forbes called testi...Brownstone Research | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just...Pennie Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.